Merck Price to Free Cash Flow Ratio 2010-2023 | MRK

Historical price to free cash flow ratio values for Merck (MRK) since 2010. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Merck Price to Free Cash Flow Ratio Historical Data
Date Stock Price TTM FCF per Share Price to FCF Ratio
2024-05-17 131.19 36.55
2023-12-31 108.33 $3.59 30.18
2023-09-30 101.56 $5.17 19.63
2023-06-30 113.07 $4.26 26.55
2023-03-31 103.55 $4.43 23.39
2022-12-31 107.26 $5.79 18.54
2022-09-30 82.71 $6.03 13.73
2022-06-30 86.87 $5.70 15.25
2022-03-31 77.55 $4.84 16.01
2021-12-31 71.80 $3.42 21.01
2021-09-30 69.71 $2.67 26.15
2021-06-30 71.54 $1.29 55.48
2021-03-31 70.31 $1.43 49.29
2020-12-31 73.96 $1.25 58.95
2020-09-30 74.40 $0.16 462.95
2020-06-30 68.86 $1.38 49.73
2020-03-31 67.97 $1.74 38.98
2019-12-31 79.71 $2.14 37.29
2019-09-30 73.27 $3.45 21.26
2019-06-30 72.50 $2.98 24.36
2019-03-31 71.44 $3.13 22.86
2018-12-31 65.20 $3.10 21.03
2018-09-30 60.10 $3.31 18.18
2018-06-30 51.07 $1.92 26.64
2018-03-31 45.47 $1.94 23.44
2017-12-31 46.57 $1.66 28.05
2017-09-30 52.54 $1.57 33.54
2017-06-30 52.22 $3.07 17.02
2017-03-31 51.39 $-0.84 0.00
2016-12-31 47.27 $0.50 94.80
2016-09-30 49.73 $0.46 108.65
2016-06-30 45.57 $0.39 116.27
2015-12-31 41.08 $3.96 10.37
2015-09-30 38.08 $2.11 18.06
2015-06-30 43.52 $2.45 17.79
2015-03-31 43.60 $2.28 19.13
2014-12-31 42.74 $2.28 18.76
2014-09-30 44.28 $3.65 12.12
2014-06-30 42.89 $3.49 12.30
2014-03-31 41.78 $3.45 12.12
2013-12-31 36.54 $3.37 10.83
2013-09-30 34.45 $2.87 11.99
2013-06-30 33.31 $2.52 13.22
2013-03-31 31.41 $2.68 11.71
2012-12-31 28.82 $2.62 10.99
2012-09-30 31.44 $3.13 10.03
2012-06-30 28.83 $3.60 8.01
2012-03-31 26.23 $3.59 7.31
2011-12-31 25.48 $3.45 7.39
2011-09-30 21.83 $3.51 6.22
2011-06-30 23.29 $2.90 8.04
2011-03-31 21.55 $3.06 7.05
2010-12-31 23.26 $2.93 7.94
2010-09-30 23.51 $2.19 10.73
2010-06-30 22.10 $2.13 10.36
2010-03-31 23.35 $0.88 26.43
2009-12-31 22.61 $0.74 30.58
2016-03-31 41.51 $0.79 52.28
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $332.279B $60.115B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $731.812B 105.77
Novo Nordisk (NVO) Denmark $591.861B 45.48
Johnson & Johnson (JNJ) United States $372.169B 14.78
AbbVie (ABBV) United States $293.876B 15.18
AstraZeneca (AZN) United Kingdom $238.424B 20.73
Novartis AG (NVS) Switzerland $209.653B 14.86
Pfizer (PFE) United States $162.291B 20.17
Sanofi (SNY) $123.116B 11.62
Innoviva (INVA) United States $0.998B 7.01